Video Series

A medical professional addresses the social aspects of bronchiectasis, emphasizing patients' embarrassment due to productive coughing in public spaces like grocery stores and churches, as well as the psychological challenges of planning travel and vacations due to the unpredictability of exacerbations, which can lead to social isolation.

Robert Gabbay, MD, PhD, gives closing thoughts and advocates that continuous glucose monitors should be supplied for all insulin-dependent diabetes patients, including at initial diagnosis, to facilitate self-management and tighter control of this disease.

The panel has an in-depth discussion on improving diversity in clinical trials. They discuss ways to increase minority participation through community partnerships, including providing transportation, lodging, and other resources needed to enable participation.

Pam R. Taub, MD, FACC, FASPC, leads a discussion on implicit bias and mandated trainings for medical license renewal that help eliminate bias and address disparities.

A medical professional explores the management of bronchiectasis exacerbations, detailing the significance of sputum color, the potential for hemoptysis, and the exacerbation of comorbidities such as COPD and asthma.

Panelists discuss desired innovations in health care technology, as well as incentives to further integrate these new technologies into patient care.

Panelists discuss technological developments, including virtual visits and mobile health, and their role in improving cardiovascular care.

A professional discussion on diagnosing type 1 diabetes based on autoimmune antibodies, oral glucose tolerance test results, fasting glucose, and hemoglobin A1C levels.

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

Pamela J. McShane, MD, discusses the long-term outcome of patients with bronchiectasis and emphasizes the crucial role of radiographic imaging in diagnosing the disease.

A panel of experts discuss improving collaboration between health systems and managed care organizations to ensure optimal outcomes for patients with rare diseases.

Robert Gabbay, MD, PhD, discusses research showing that early intervention with a recent FDA-approved therapy can delay the onset of type 1 diabetes by an average of 2-3 years.

Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.

Kimberly C. Chen, DO, MSHLM, discusses subscription models and warranties for cell and gene therapies, exploring their impact on patient access and financial sustainability.

Medical experts discuss potential solutions to mitigate preventable challenges in cardiovascular disease treatment, such as reforming the fee-for-service system and implementing value-based care models.

Panelists discuss financial obstacles, out-of-pocket costs, prior authorizations, and the inpatient/outpatient care paradigm.

The panel discusses disparities in the quality of care received by Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.

The panel discusses remaining gaps in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment and shares perspectives on optimal practices and care settings for managing this disease.

Pamela J. McShane, MD, explores the clinical manifestations of bronchiectasis, including productive chronic cough, hemoptysis, and recurrent respiratory infections, while emphasizing the importance of CT scans in revealing improper airway narrowing and addressing the misdiagnosis of COPD and asthma.

A medical professional discusses the process of diagnosis of type 1 diabetes, including challenges that emerge during screening and considerations for improving the pathway.

Ryan Haumschild, PharmD, MS, MBA, leads a discussion on factors that influence coverage of non-oncology gene therapies, exploring the balance between long-term cost savings and high initial prices, patient selection, and the durability of effect for these therapies.

Health care professionals discuss the challenges related to developing and interpreting clinical data for rare disease therapies to guide payer coverage decisions.

Vivian Tambe Ebot-Tar, PharmD, MBA, leads a discussion on value-based care models based on real-world evidence for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Medical experts emphasize the importance of partnering with community leaders to address social determinants of health that act as barriers to care.

The panel discusses the availability of data on cardiovascular outcomes related to gender and minority disparities, including data collection, reporting standards, and minority participation in clinical trials.

An expert reviews risk factors for type 1 diabetes including autoimmune disease and family history, along with the role of autoimmune antibody screening to enable early disease detection, though access to these specialized tests can be limited.

Kimberly C. Chen, DO, MSHLM, and Jessica Nance, MD, MS, discuss clinical evidence requirements, pricing considerations, and innovative financing models to provide sustainable coverage for the growing pipeline of gene therapies.

Emma Ciafaloni, MD, FAAN, and Jessica Nance, MD, MS, discuss promising developments in gene therapy, highlighting long-term efficacy, enhanced target effects, and the potential impact of early screening on treatment outcomes for genetic diseases.